Ligand–receptor interaction platforms and their applications for drug discovery
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The study of drug-target interactions is essential for the understanding of biological processes and for the efforts to develop new therapeutic molecules. Increased ligand-binding assays have coincided with the advances in reagents, detection and instrumentation technologies, the expansion in therapeutic targets of interest, and the increasingly recognized importance of biochemical aspects of drug-target interactions in determining the clinical performance of drug molecules. Nowadays, ligand-binding assays can determine every aspect of many drug-target interactions. AREAS COVERED: Given that ligand-target interactions are very diverse, the author has decided to focus on the binding of small molecules to protein targets. This article first reviews the key biochemical aspects of drug-target interactions, and then discusses the detection principles of various ligand-binding techniques in the context of their primary applications for drug discovery and development. EXPERT OPINION: Equilibrium-binding affinity should not be used as a solo indicator for the in vivo pharmacology of drugs. The clinical relevance of drug-binding kinetics demands high throughput kinetics early in drug discovery. The dependence of ligand binding and function on the conformation of targets necessitates solution-based and whole cell-based ligand-binding assays. The increasing need to examine ligand binding at the proteome level, driven by the clinical importance of the polypharmacology of ligands, has started to make the structure-based in silico binding screen an indispensable technique for drug discovery and development. Integration of different ligand-binding assays is important to improve the efficiency of the drug discovery and development process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058 · cited 1×
“A variety of in silico approaches including virtual screening [117], molecular docking [118], and cheminformatics-based screening [119,120] have started making impacts on drug discovery and development.”
BackgroundHopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“Our improved understanding of the molecular basis of human diseases has expanded the list of targets used for developing new therapeutics [1,2].”
BackgroundCrystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009 · cited 1×
“Several receptors have distinct structures complexed with either different ligands or Gas protein [138].”
BackgroundThe structure and function of G-protein-coupled receptors
Rosenbaum, D. M., Rasmussen, S. G. F., & Kobilka, B. K. (2009) · Nature · doi:10.1038/nature08144 · Cited by 2,534
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403 · cited 2×
“Since then, the concept of ligand efficiency has been extended to include several new matrices including binding efficiency index (affinity/molecular weight), percentage efficiency index (% inhibition/molecular weight), surfacebinding efficiency index (affinity/van der Waals polar surface area) [37-39], kinetic effici…”
BackgroundProduction of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032 · cited 1×
“Advances in molecular cloning and cell culture technologies have made it routine to produce many target proteins with high quality, so it is affordable to perform large-scale biochemical analysis of drug--target interactions [3].”
BackgroundThe role of dynamic conformational ensembles in biomolecular recognition
Boehr, D. D., Nussinov, R., & Wright, P. E. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.232 · Cited by 2,008
Cited by
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
A Structure-Based Drug Discovery Paradigm
Batool, M., Ahmad, B., & Choi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112783 · Cited by 744
High-Throughput Screening: today’s biochemical and cell-based approaches
Blay, V., Tolani, B., Ho, S. P., & Arkin, M. R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.024 · Cited by 387
Surface plasmon resonance (SPR) biosensors for food allergen detection in food matrices
Zhou, J., Qi, Q., Wang, C., Qian, Y., Liu, G., Wang, Y., & Fu, L. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111449 · Cited by 350
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends: Miniperspective
Zhan, P., Pannecouque, C., De Clercq, E., & Liu, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00497 · Cited by 303
Integrating Molecular Docking and Molecular Dynamics Simulations
Santos, L. H. S., Ferreira, R. S., & Caffarena, E. R. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9752-7_2 · Cited by 285
Surface Plasmon Resonance Imaging Sensors: A Review
Wong, C. L., & Olivo, M. (2014) · Plasmonics · doi:10.1007/s11468-013-9662-3 · Cited by 259
Gabriel, J., Höfner, G., & Wanner, K. T. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00665 · Cited by 20
“So far, a vast number of approaches to monitor target-ligand binding with different detection techniques has been established (Fang, 2012).”
BackgroundOjha, A. A., Votapka, L. W., & Amaro, R. E. (2023) · Chemical Science · doi:10.1039/d3sc04195f · Cited by 19
Gabriel, J., Höfner, G., & Wanner, K. T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112598 · Cited by 3
Metadata
- Authors
- Fang, Y.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2012-08-04
- Volume
- 7
- Issue
- 10
- Pages
- 969-988
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W1977490022
- Cited by
- 124
- References
- 21
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.